{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:47:01Z","timestamp":1790855221369,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":3932,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.ymthe.2005.08.006","type":"journal-article","created":{"date-parts":[[2005,10,6]],"date-time":"2005-10-06T11:11:29Z","timestamp":1128597089000},"page":"127-134","source":"Crossref","is-referenced-by-count":37,"title":["Fully Deleted Adenovirus Persistently Expressing GAA Accomplishes Long-Term Skeletal Muscle Glycogen Correction in Tolerant and Nontolerant GSD-II Mice"],"prefix":"10.1016","volume":"13","author":[{"given":"Anne","family":"Kiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary C.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delila","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna J.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Amalfitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2005.08.006_bib1","series-title":"Glycogen Storage Disease Type II: Acid Alpha-glucosidase (Acid Maltase) Deficiency","first-page":"3389","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymthe.2005.08.006_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymthe.2005.08.006_bib3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2005.08.006_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1357-4310(00)01694-4","article-title":"Towards a molecular therapy for glycogen storage disease type II (Pompe disease)","volume":"6","author":"Chen","year":"2000","journal-title":"Mol. Med. Today"},{"key":"10.1016\/j.ymthe.2005.08.006_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1212\/WNL.52.4.851","article-title":"A diagnostic protocol for adult-onset glycogen storage disease type II","volume":"52","author":"Ausems","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2005.08.006_bib6","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.08.006_bib7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/jgm.355","article-title":"Multiple muscles in the AMD quail can be \u201ccross-corrected\u201d of pathologic glycogen accumulation after intravenous injection of an [E1\u2212, polymerase\u2212] adenovirus vector encoding human acid-alpha-glucosidase","volume":"5","author":"McVie-Wylie","year":"2003","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2005.08.006_bib8","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1128\/JVI.71.7.5189-5196.1997","article-title":"Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo","volume":"71","author":"Wadsworth","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2005.08.006_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/10430349950018805","article-title":"Persistence of an [E1\u2212, polymerase\u2212] adenovirus vector despite transduction of a neoantigen into immune-competent mice","volume":"10","author":"Hu","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1089\/104303401750195917","article-title":"Long-term efficacy after [E1\u2212, polymerase\u2212] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice","volume":"12","author":"Ding","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib11","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.gt.3302494","article-title":"Primary adenovirus-specific cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevation","volume":"12","author":"Chen","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib12","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/mthe.2002.0563","article-title":"Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction","volume":"5","author":"Ding","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1525-0016(02)90716-1","article-title":"Glycogen stored in skeletal but not in cardiac muscle in acid \u03b1-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme","volume":"6","author":"Raben","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib14","first-page":"789","article-title":"Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model","volume":"8","author":"Xu","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jgm.660","article-title":"Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA","volume":"7","author":"Xu","year":"2005","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2005.08.006_bib16","doi-asserted-by":"crossref","first-page":"13282","DOI":"10.1073\/pnas.241506298","article-title":"Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector","volume":"98","author":"Kim","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.08.006_bib17","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1161\/01.CIR.103.9.1274","article-title":"Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor","volume":"103","author":"Oka","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2005.08.006_bib18","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/sj.gt.3302310","article-title":"Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia","volume":"11","author":"Nomura","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1525-0016(03)00022-4","article-title":"Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus\u2013AAV vector","volume":"7","author":"Sun","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/104303401300042447","article-title":"Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease","volume":"12","author":"Pauly","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib21","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/hmg\/10.19.2039","article-title":"Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy","volume":"10","author":"Raben","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2005.08.006_bib22","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1128\/JVI.70.10.7209-7212.1996","article-title":"Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs","volume":"70","author":"Yang","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2005.08.006_bib23","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1089\/hum.1997.8.15-1797","article-title":"Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector","volume":"8","author":"Svensson","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib24","doi-asserted-by":"crossref","first-page":"11557","DOI":"10.1073\/pnas.91.24.11557","article-title":"Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus","volume":"91","author":"Tripathy","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.08.006_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nm0596-545","article-title":"Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors","volume":"2","author":"Tripathy","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2005.08.006_bib26","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1089\/10430349950017455","article-title":"Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors","volume":"10","author":"Pastore","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/sj.gt.3301409","article-title":"Intravenous administration of an E1\/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL\/6 mice","volume":"8","author":"Fields","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of \u03b1-galactosidase A and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1006\/mthe.2001.0496","article-title":"Immune evasion by muscle-specific gene expression in dystrophic muscle","volume":"4","author":"Hartigan-O'Connor","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/1566523024605618","article-title":"Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy","volume":"2","author":"Amalfitano","year":"2002","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib31","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood.V91.9.3273","article-title":"Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy","volume":"91","author":"Connelly","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2005.08.006_bib32","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ymthe.2003.08.014","article-title":"Improved system for helper-dependent adenovirus vector production","volume":"8","author":"Palmer","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.08.006_bib33","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2005.08.006_bib34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1022998010833","article-title":"Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice","volume":"12","author":"Raben","year":"2003","journal-title":"Transgenic Res."},{"key":"10.1016\/j.ymthe.2005.08.006_bib35","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1089\/104303403322611737","article-title":"Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors","volume":"14","author":"Everett","year":"2003","journal-title":"Hum. Gene Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001605015546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001605015546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T04:57:01Z","timestamp":1586494621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001605015546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S1525001605015546"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2005.08.006","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}